IPO News | Stem cell therapy developer Pollon Life secretly applied for Hong Kong listing to raise about US$300 million

Zhitongcaijing · 10/29/2025 05:49

Zhitong Finance App learned that according to media sources, Pollon Life, a Chinese stem cell therapy developer, has applied for listing in Hong Kong in a confidential manner, raising about 300 million US dollars. People familiar with the matter said that Pollon Life has received support from Ma Yun's Yunfeng Capital and is cooperating with CCB International, CICC, and UBS Group to advance the listing plan. Relevant discussions are still ongoing, and details such as the size of the IPO may be adjusted.

Pollon Life, previously known as Platinum Biotech, has developed the first stem cell therapy emimetoxel injection approved for marketing in China at the beginning of the year. It is indicated for treating acute graft-versus-host disease where hormone therapy fails, mainly gastrointestinal involvement in people aged 14 and over.